← Home / CORCEPT THERAPEUTICS INC (CORT)
Stock Analysis
CORCEPT THERAPEUTICS INC (CORT)
CORT
CORT · Market data
118.32 +27.29%
Track CORT in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when CORT price is:
52W Range Position
100%
LOWMIDHIGH
Trend
Constructive
Momentum
Neutral
Updated: 2026-07-31 11:41 UTC
WOI Investment Thesis
Constructive
Watch confirmation and invalidation levels before acting.
⚖️
✓
Fundamentals
Moderate / Negative
✓
Price Structure
Constructive
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
82.75
↗
Break Above
Confirmation improves above resistance.
—
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below 82.75
Recent Company Events
SEC VERIFIED
Latest material filings
MAY
28
●
Management / Board
MEDIUM
CORT board and management update
On May 21, 2026, Corcept Therapeutics Incorporated (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”).
8-K Filing • SEC EDGAR
What's Driving CORT?
📈 Technical recovery is improving
Momentum is Neutral. Watch — for confirmation and 82.75 for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
Below 82.75
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
▲
No confirmed breakout yet. Watch the next level and momentum behavior.
RSI(14)
76.6
Price Chart
CORT — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-30
Spec
Speculative premium
Valuation is very demanding relative to current fundamentals; expectations are high.
Market Cap
$13.5B
Company size
EV
$13.4B
Debt-adjusted value
P/E
285.1
Very high
P/S
17.6
Premium
P/B
21.2
Very high
EV/Sales
17.5
Premium
EV/EBIT
299.6
Very high
P/FCF
112.7
Very high
FCF Yield
0.89%
Cash return
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial pressure is elevated
Financial conditions require selective monitoring.
↗
Revenue Growth
Moderate
●
Profitability
Negative
≈
Cash Flow
Pressured
⚖
Balance Sheet
Strong
💵 Revenue
164.90M
≈ Moderate
📈 Net Income
-31.76M
↘ Negative
🧮 EPS (Basic)
-0.30
↘ Negative
CORCEPT THERAPEUTICS INC
Related Opportunities